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Urbana-Champaign and Millennium Pharmaceuticals, Inc.
The statistical tests that are commonly used for detecting mean
or median treatment effects suffer from low power when the two dis-
tribution functions differ only in the upper (or lower) tail, as in the
assessment of the Total Sharp Score (TSS) under different treatments
for rheumatoid arthritis. In this article, we propose a more powerful
test that detects treatment effects through the expected shortfalls.
We show how the expected shortfall can be adjusted for covariates,
and demonstrate that the proposed test can achieve a substantial
sample size reduction over the conventional tests on the mean effects.
1. Introduction. We consider the problem of testing the hypothesis of
no treatment effect against a class of alternatives where the two outcome
distributions differ only or mainly in the right tail. As demonstrated in
some recent trials of rheumatoid arthritis therapies in van der Heijde et al.
(2006) and Kremer et al. (2006), the changes in Total Sharp Scores, the
primary measurements of the treatment effects on prevention of structural
damage, are nearly identical for most therapies for nearly 75% of the patient
population, but the difference lies in the most challenging 25% of the patient
population where a less effective treatment loses its efficacy, resulting in a
heavy right tail in its outcome distribution. The two-sample t-test or its
regression counterpart in covariate-adjusted linear models is commonly used
for detecting the treatment effects, but due to skewness and heavy-tails of the
distributions, the test does not have satisfactory power. Nonparametric tests
on the median differences, for example, would fare even worse in such cases,
because the median differences are often negligible among those therapies.
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A natural test in this type of applications is to focus on the average in
one tail, or the expected tail loss (aka expected shortfall). In finance, this is
often referred to as the conditional value at risk (CVaR), for measuring the
risk of a portfolio. In our context, a treatment is said to be more effective if
it has a smaller expected shortfall, where the expected shortfall is defined to
be the conditional mean of the outcome (e.g., change in Total Sharp Score)
above the τ th quantile. In this paper, τ will be taken to be a user-specified
value (e.g., 0.75), but a good choice of τ clearly depends on the area of
applications. In finance, the most relevant choices of τ fall above 0.90.
A two-sample comparison of the expected shortfalls is not difficult, as it
falls into the well-known theory of the L-statistic. In fact, there are also a
large number of other tests that one can use to compare tails of two outcome
distributions, but few have been developed to adjust for covariates. The
purpose of this paper is to develop a simple test for testing the hypothesis
on the treatment effect adjusting for certain covariates; the proposed test
uses the COV ariate-adjusted Expected Shortfall (COVES).
Our work starts with a brief introduction to our motivating example on
the TSS for rheumatoid arthritis therapies in Section 2. In Section 3, we
propose an appropriate treatment effect size of covariate-adjusted expected
shortfall, followed by a new test for detecting differences in the treatment
effects. The large sample theory for the proposed test is given here. In Sec-
tion 4, we compare the proposed COVES test with the t-test based on the
least squares regression in empirical power. In particular, we show that when
the outcome distributions resemble those of the TSS, the COVES test has a
clear advantage in reducing sample sizes in clinical trials. The basic idea and
methodology developed in this paper apply to other problems of comparing
two covariate-adjusted tails of outcome distributions. In Section 5, we pro-
vide a diagnostic tool that can be used to gauge the need for the proposed
test and to guide the selection of τ . Section 6 concludes the paper with some
additional remarks about the COVES test.
2. A primer on total sharp scores. Rheumatoid arthritis (RA) is a chronic
disabling disease that causes destruction of joint cartilage and erosion of ad-
jacent bones. In RA clinical trials, TSS is used to measure the treatment
effect of RA drugs on prevention of structural damage to the joints. It con-
sists of two components, erosion score and score for joint space narrowing
(JSN), which are obtained through examination of hand and/or feet joints
with radiographic methods. The first description of TSS is given by Sharp
et al. (1971), but TSS has been modified in later studies. The example pre-
sented in this paper is based on van der Heijde’s modification of TSS scoring
system [van der Heijde (2000)], which is based on examination of 16 areas
for erosions and 15 for joint space narrowing in each hand. The erosion score
per joint ranges from 0 to 5 with 0 representing a normal condition and 5
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Fig. 1. This figure, reproduced from van der Heijde et al. (2006), shows that the changes
in TSS in the TEMPO trials differ mostly in the upper tails.
the most severe disease, and thus the total erosion score ranges from 0 to
160 (16 areas by 2 hands by 5). The JSN score ranges from 0 to 4 per joint
with higher score representing more severe disease, which leads to a range of
0 to 120 (15 areas by 2 hands by 4) for the total JSN score. Therefore, the
range of TSS is 0 – 280. The primary interest is the change from baseline in
TSS in one or two years.
The change in TSS has a highly skewed distribution under any known
treatment. In the TEMPO trial [van der Heijde et al. (2006)] comparing
Methotrexate, Etanercept, and the combination therapy of Etanercept and
Methotrexate, the three treatments are similarly effective for about 75% of
the patients whose conditions improved or showed no or little progression
from the baseline; see Figure 1. Medians for all three groups are around 0.
Treatment differences come from the 25% of the patients with the most pro-
gressive diseases. In other words, the differences in treatment effects are not
attributed to a location-scale change in the distributions. The distributions
of clinical data from several other major RA trials [Kremer et al. (2006);
Keystone et al. (2004); Lipsky et al. (2000)] showed similar characteristics.
It is clear that the distributions for the changes in TSS are far from nor-
mal, and the t-test is expected to lose power due to skewness and heavier-
tails that are evident in the data. Nonparametric tests on the median differ-
ences would fare even worse, because the median differences of those treat-
ments are essentially nonexistent. Researchers in some trials have considered
the chi-square tests on the proportion of patients with little disease progres-
sion by dichotomizing TSS, but there has been no agreeable cutoff point for
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dichotomization. In fact, the power of the chi-square test depends rather
critically on the cutoff point. In addition, it is difficult to perform the chi-
square test when a covariate needs to be adjusted for. A natural quantity for
distinguishing treatment effects is the expected shortfall, which averages the
changes in TSS in the upper tail. We propose to use the regression quantile
approach of Koenker and Bassett (1978) to estimate the covariate-adjusted
expected shortfall.
Later in this paper, we use a recent observational study conducted at
Brigham and Women’s Hospital and sponsored by Millennium Pharmaceu-
ticals Inc. and Biogen Idec as a basis for assessing the performance of the
proposed test. We take 150 subjects in the study, who are under active treat-
ment, and simulate a control group whose outcome distribution is chosen to
mimic the treatment difference reported in other trials. For example, in the
Adalimumab trial [Keystone et al. (2004)], the variance of the treatment
group (using the drug Adalimumab 20 mg/kg) is about half of that in the
control group (using the drug Methotrexate) with a mean difference of −1.9.
In the Abatacept trial [Kremer et al. (2006)], the variance in the Abatacept
group is about one third of that in the control group. In our simulation stud-
ies, we use the ratio of variances between 2:1 and 3:1 between two treatment
groups.
3. Proposed test: COVES. We use a dummy variable D as treatment
indicator, C as the covariate of interest, and Z as the outcome measure.
For simplicity of notation, we consider C ∈R as a univariate covariate and
D taking values 0 or 1, but the work generalizes readily for multivariate
covariates and multiple treatments. As appropriate with randomized trials,
we assume that C and D are independent. We model the τ th quantile of Z
given (D,C) as
QZ(τ |D,C) = α(τ) + δ(τ)D + γ(τ)C,(1)
where the coefficients α, δ, and γ are τ -specific. In this paper, we use τ = 0.75
for empirical studies, but refer to Section 5 for guidance on the selection of τ .
We also refer to Koenker (2005) for details on the linear regression quantile
specification.
Given data (Zi,Di,Ci) with Di = 1 for i= 1, . . . ,m and Di = 0 for i=m+
1, . . . ,m+ n, we can use the quantreg package in R to obtain the regression
quantile coefficient αˆ, δˆ, and γˆ. Then, let eˆi = Zi − αˆ − δˆDi − γˆCi as the
residuals from the τ th regression quantile. By contrast, we also write ei =
Zi−α(τ)− δ(τ)Di − γ(τ)Ci, which has zero as the τ th conditional quantile
given (Di,Ci) due to (1).
Let Yi = Zi − γˆCi be the covariate-adjusted outcome, and define the em-
pirical covariate-adjusted expected shortfall for the two groups as
COVESτ (d) =
∑
Di=d
wd,iYi, d= 0,1,
DETECTION OF TREATMENT EFFECTS 5
where wd,i = S
−1
d I(eˆi > 0) and Sd =
∑
Di=d
I(eˆi > 0). The quantity COVESτ (d)
is the average of the outcomes for group d that are above the τ th covariate-
adjusted quantile.
The proposed COVES test statistic for the hypothesis of no difference
between the two treatment groups is given as
Tτ (m,n) = COVESτ (1)−COVESτ (0).(2)
Let C¯τ (d) and e¯τ (d) be the average of Ci and ei in group d that are above
the τ th regression quantile, that is,
C¯τ (d) = S
−1
d
∑
Di=d
CiI(eˆi > 0),
e¯τ (d) = S
−1
d
∑
Di=d
(Zi −α(τ)− δ(τ)Di − γ(τ)Ci)I(eˆi > 0).
Then, the test statistic (2) can be written as
Tτ (m,n) = δ(τ)− (γˆ − γ(τ))(C¯τ (1)− C¯τ (0)) + (e¯τ (1)− e¯τ (0)),(3)
which makes it relatively easy to establish the asymptotic normality of the
test statistic as m,n→∞.
To estimate the variance of Tτ (m,n), let Nd =
∑
i I(Di = d), fi be the
conditional density function of ei given (Di,Ci) evaluated at 0, and
C∗i =Ci −N
−1
d
∑
i
CiI(Di = d),
as the orthogonal components C relative to the treatment groups. In more
general problems, we can obtain C∗ by the Gram–Schmidt orthogonalization
of the design matrix. Furthermore, let
Vd =
∑
Di=d
{eˆ2i I(eˆi > 0)} −N
−1
d
[∑
Di=d
{eˆiI(eˆi > 0)}
]2
,
Uf =
∑
i
(fiC
∗
i
2),
and
s2m,n = (1− τ)
−2(V1/m
2 + V0/n
2)
(4)
+ τ(1− τ)(C¯τ (1)− C¯τ (0))
2U−2f
(∑
i
C∗i
2
)
.
Theorem 3.1. Suppose that limm,n→∞(m+n)
−1Uf exists, E|Ci|
3 <∞,
and fi are uniformly bounded away from 0 and infinity. Under the null
hypothesis that FZ|C,D=1 = FZ|C,D=0, we have
TCOVESτ (m,n)/sm,n→N(0,1) asm,n→∞.
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The proof of Theorem 3.1 is given in the Appendix, but to use the asymp-
totic normality for testing the null hypothesis of no treatment effects, we
need a consistent estimate of Uf . If ei in each group (corresponding to Di = 0
or 1) follows a common distribution, then a kernel density estimate can be
used to estimate the common density at 0 from eˆi in the dth group. If the
conditional densities vary with Ci, it is not possible to estimate each fi
consistently, but Uf , a linear combination of the fi’s, can still be consis-
tently estimated; see He, Fung and Zhu (2002) and Koenker (2005) for more
details. For the empirical investigations in this paper, the proposed test is
carried out using a kernel density estimate, density, in R on each treatment
group.
4. Empirical investigations. In this section, we report some empirical
power studies of the proposed test based on Monte Carlo simulations. The
first study is constructed based on the data we obtained from a recent study
on an undisclosed therapy to treat RA at the Brigham and Women’s Hospi-
tal in Boston. The other studies are constructed with other types of distri-
butions in mind. Together, we find that the proposed COVES test greatly
outperforms the usual regression tests on the mean differences when the
group differences occur at one tail of the distributions.
4.1. Targeted study on TSS. We use the empirical distributions, F , of
the TSS changes of 150 patients in the Brigham and Women’s Hospital study
as the underlying distribution for the group d= 1. We take the baseline TSS
as the covariate in the analysis, whose empirical distribution for the group
d= 1 will be denoted as G.
The data from the control group (with d= 0) will be simulated as
C =G−1(u), Z = F−1(u) + 8|u− 0.65|1/4I(u > 0.65),
where u is a uniform random number in (0, 1). Clearly, the control group
has a heavier right tail in its outcome, but the covariate C has the same
distribution in both groups. In this setting, the variance of the control group
is about twice that of the treatment group. Table 1 and Figure 2 summarize
the differences of the two groups.
Table 1
Differences in the τ th quantiles and in the mean, with the last column as the ratio of the
variances between the control group (d= 0) and the treatment group (d= 1)
τ 0.5 0.6 0.7 0.75 0.8 0.9 0.99 Mean Variance ratio
0 0 3.72 4.53 4.96 5.64 6.02 1.74 2.03
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Fig. 2. Quantile function of the TSS change shows that the groups differ mostly in the
upper tails.
Fig. 3. Statistical powers of three tests in the targeted study on TSS as functions of
sample size m= n. The ES test ignores the covariate in the model.
The power functions for the COVES test with τ = 0.75 and the t-test from
linear regression are shown in Figure 3 with sample sizes up to m= n= 350.
For comparison, we also include in the figure the power curve for the test
based on expected shortfalls (ES) without adjusting for the baseline TSS.
Table 2 provides the sample sizes needed to reach a power of 0.90 in clinical
trials with m= n as well as m= 2n. It is common in clinical experiments to
allocate twice as many patients to the treatment group when the treatment
is believed to be effective. In this case, the baseline TSS does not play a
significant role, so the statistical power for detecting the treatment effect
8 X. HE, Y.-H. HSU AND M. HU
Table 2
Sample sizes needed to reach power 0.9. The cases
of m= n and m= 2n are included
Sample size (m,n)
COVES test (τ = 0.75) (120, 120) or (172, 86)
t-test (306, 306) or (450, 225)
Table 3
Difference of the two groups at η = 1.35, with the last column for
the ratio of error variances
τ 0.5 0.6 0.7 0.75 0.8 0.9 Mean Var ratio
0 0.34 0.70 0.91 1.13 1.72 0.54 2.97
has no gain by adjusting the covariate in the analysis. However, the results
show that the COVES test is clearly outperforming the t-test, and the latter
would require a trial that is more than double in size.
4.2. More simulation studies. We consider data generated from
Zi = 5+ γCi + {1 + ηI(ei > 0)I(Di = 0)}ei,(5)
where ei ∼ N(0,1), and η is either 0 (under the null hypothesis) or 1.35
(under the alternative hypothesis). The coefficient γ and the distribution
for the covariate Ci will be specified later. Clearly, the control group (d= 0)
has a heavier right tail. When η = 1.35, the error variance of the control
group (d = 0) is about triple that of the treatment group (d = 1) under
this model. Table 3 summarizes the differences of the two groups under the
alternative hypothesis.
We will consider four scenarios for the effects of the covariate in the anal-
ysis:
• Scenario 1, no covariate effect: we take Ci from N(2.5,0.5
2), with γ = 0.
• Scenario 2, a common covariate effect: we take Ci from N(2.5,0.5
2), with
γ = 1.
• Scenario 3, a covariate distribution that varies with treatment groups: we
take Ci from N(2.5,0.5
2) for d= 0, but from N(3.0,0.52) for d= 1, with
γ = 1.
• Scenario 4, a covariate distribution that has a scale change across treat-
ment groups: we take Ci from N(2.5,0.5
2) for d= 0, but from N(2.5,1.0)
for d= 1, with γ = 1.
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Table 4
Simulation comparisons for the COVES test versus t-test for linear models. The sample
sizes under two conditions m= n and m= 2n are given
COVES test t-test
Type I error Sample size (m,n) Type I error Sample size (m,n)
(m,n) = needed to reach (m,n) = needed to reach
Scenario (50, 50) power 0.9 (50, 50) power 0.9
1 0.046 (51, 51) or (92, 46) 0.050 (140, 140) or (202, 101)
2 0.051 (51, 51) or (92, 46) 0.049 (140, 140) or (202, 101)
3 0.048 (59, 59) or (100, 50) 0.050 (177, 177) or (240, 120)
4 0.053 (50, 50) or (92, 46) 0.052 (140, 140) or (200, 100)
Scenarios 3 and 4 are unlikely for randomized trials, but we include them
in the study to examine the robustness of the COVES test when the covariate
distributions vary to some extent with the treatment groups. The type I
errors of the COVES test and the t-test under these scenarios are controlled
to stay close to the nominal level of 0.05. The following table reports the
type I errors at the sample size ofm= n= 50. It also reports the sample sizes
needed to reach power of 0.90 in each scenario under two design conditions:
m= n and m= 2n, respectively.
The results clearly show the efficiency of the COVES test. In Scenarios
2–4, the adjustment of the covariate is important, because the ES test con-
sidered in Section 4.1 would not be valid, and thus it is not presented in this
subsection.
5. A diagnostic tool for COVES. When preliminary or full data are
available, it is often helpful to have a simple diagnostic tool that points to a
case in favor of the COVES test. We suggest examining the quantile function
plot, as used in Figure 1, but applied to the covariate-adjusted outcomes
defined in Section 3. When the quantiles of covariate-adjusted outcomes
from different treatment groups differ mostly in one tail, we have a clear case
in favor of the COVES test or a similar test that focuses on the tail. In fact,
the plot can also suggest an appropriate level of τ to be used for COVES.
To illustrate this point, we simulated one data set of size m= n= 60 from
Scenario 3 in Section 4.2 with η = 1.35 in model (5). Unsure about a good
choice of τ , we considered using the covariate-adjusted outcomes from three
quantile levels 0.5, 0.75, and 0.9, and examined the resulting quantile plots
in Figure 4. No matter which quantile level we started with, the quantile
plots of the covariate-adjusted outcomes look similar, and they all suggest
that the COVES test with τ around 0.75 would be a good choice. On the
other hand, if the quantile functions of different treatment groups show a
vertical shift, we would then favor the t-test to the COVES test.
10 X. HE, Y.-H. HSU AND M. HU
(a) (b)
(c)
Fig. 4. Quantile function plots of the covariate-adjusted outcomes; the adjustments are
made based on regression quantile at ( a) τ = 0.5, (b) τ = 0.75, ( c) τ = 0.9. The diagnostic
plots are insensitive to the initial choice of τ .
6. Conclusions. The proposed COVES test aims to detect treatment ef-
fects that are reflected mostly in the upper (or lower) tail of the outcome
distributions. The test is powered up by the use of the expected shortfall as a
natural differentiating quantity in such applications. We find that the regres-
sion quantile methodology is appropriate and convenient for computing the
covariate-adjusted expected shortfall in the test. Our study on the change of
the Total Sharp Scores due to different treatments on rheumatoid arthritis
shows that a substantial sample size reduction over the conventional t-test
based on linear models can be achieved.
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In this paper, we used τ = 0.75 in the proposed COVES test, because
it serves two purposes in the application. First, earlier studies have shown
conventional rheumatoid arthritis treatments are effective for nearly 75% of
the patient population, so it is less meaningful to detect differences below
the 75th percentile. Second, a more effective treatment should work well for
a substantial portion of the patients, so if we set τ to be too high in the
COVES test, a significant difference in the upper tail might be difficult to
detect statistically. Finally, we note that the development of the COVES
test in this paper was made in response to the randomized clinical studies
on rheumatoid arthritis treatments, but the basic idea and the methodology
clearly generalize to other problems (where tail differences of possibly other
τ values are) of interest. In general, we suggest using quantile function plots
on covariate-adjusted outcomes as a simple diagnostic tool for suggesting a
good choice of τ .
APPENDIX: SKETCH OF PROOF
The following lemma follows directly from the consistency and the Ba-
hadur representation of regression quantile estimators; see Koenker [(2005),
Section 4.3] and He and Shao (1996).
Lemma 1. If {(Zi,Di,Ci)} is a random sample satisfying (1), limm,n→∞(m+
n)−1Uf exists, E|Ci|
3 <∞, and fi are uniformly bounded away from 0 and
infinity, then we have the Bahadur representation on γˆ
γˆ − γ(τ) =−U−1f
∑
i
C∗i I(ei < 0) + op((m+ n)
−1/2),
and the representation on e¯τ (d)
e¯τ (d)−
{∑
Di=d
I(ei > 0)
}−1 ∑
Di=d
eiI(ei > 0) = op((m+ n)
−1/2),
where Uf =
∑
i(fiC
∗2
i ), fi is the conditional density function of ei given
(Di,Ci) evaluated at 0, and C
∗
i =Ci −N
−1
d
∑
iCiI(Di = d).
Proof of Theorem 3.1. By replacing eˆi in Tτ (m,n) by ei and using
the results in Lemma 1, we approximate Tτ (m,n) by
T ∗τ (m,n) = δ(τ) +
[
{(1− τ)m}−1
∑
Di=1
I(ei > 0)ei
− (C¯τ (1)− C¯τ (0))U
−1
f
∑
Di=1
C∗i I(ei ≥ 0)
]
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−
[
{(1− τ)n}−1
∑
Di=0
I(ei > 0)ei
+ (C¯τ (1)− C¯τ (0))U
−1
f
∑
Di=0
C∗i I(ei ≥ 0)
]
.
It is clear that E(T ∗τ (m,n)) = δ(τ) = 0 under H0, and T
∗
τ (m,n) is asymp-
totically normal, with
var(T ∗τ (m,n))
= {(1− τ)m}−2
∑
Di=1
(E{e2i I(ei > 0)} − [E{eiI(ei > 0)}]
2)
+ τ(1− τ)(C¯τ (1)− C¯τ (0))
2U−2f
∑
i
(C∗i )
2
+ {(1− τ)n}−2
∑
Di=0
(E{e2i I(ei > 0)} − [E{eiI(ei > 0)}]
2).
Again, by Lemma 1 and Tτ (m,n)−T
∗
τ (m,n) = op((m+n)
−1/2), the asymp-
totic normality of Theorem 3.1 follows. 
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